Vertex Pharmaceuticals Founder Joshua Boger Has Sold $184 Million in VRTX Stock Across 1,769 Transactions
Joshua Boger, founder and former CEO of Vertex Pharmaceuticals, has filed 1,769 insider transactions totaling $184 million in sales, spanning the company's transformation from biotech startup to cystic fibrosis franchise leader.
Joshua Boger, founder and former CEO of Vertex Pharmaceuticals (VRTX), has sold $184 million in company stock across 1,769 insider transactions. Boger founded Vertex in 1989 and led the company through its early decades before stepping down as CEO in 2009, but he has continued filing as an insider through his remaining stake. His selling record spans the company's entire journey from biotech startup to the dominant franchise in cystic fibrosis treatment.
The Numbers
| Metric | Value |
|---|---|
| Career Sell Value | $184 million |
| Total Transactions | 1,769 |
| Last Transaction | Jun 23, 2025 |
| Career Buy Value | $0 |
What It Means
Boger's $184 million in career sales reflects decades of founder monetization at a company that has dramatically increased in value since his tenure. Vertex now commands a market cap above $100 billion, driven by its cystic fibrosis franchise (Trikafta/Kaftrio) and pipeline in pain, kidney disease, and gene editing. Boger's selling was most active during the earlier years when VRTX traded between $10-100; the stock's surge past $400 has made the remaining shares in his filing record exponentially more valuable.
With zero career purchases and a gradual selling pattern spanning nearly two decades, Boger fits the classic founder-diversifier profile. His 1,769 transactions — an unusually high count — reflect the granular execution of a long-running 10b5-1 plan that sold small lots at frequent intervals. His last filing in June 2025 suggests he still has a reportable position, though it has been substantially reduced from its peak.
What to Watch
- Whether Boger's filing activity continues to slow, potentially signaling an approaching end to his insider filing obligations as his remaining stake decreases
- Vertex's pipeline catalysts in pain (VX-548) and gene editing, which could drive the next leg of the stock's appreciation
- Broader insider sentiment at Vertex — if multiple insiders are selling simultaneously, it carries more weight than a single founder's systematic program
Related Research
Explore all researchAmeriprise Financial's 11,224-position portfolio has the lowest top-5 concentration of any mega-filer at 14.8%. Netflix shares surged 943%, confirming an institutional consensus trade across $2.7 trillion in combined AUM. Salesforce built 82%.
Mar 6, 2026
NWF Advisory Services built a blended portfolio in Q4 2025: Berkshire for quality, XLK for tech beta, VOO and IVV for benchmark exposure, and a fast-rising Micron line for a more specific semiconductor view.
Mar 6, 2026
Ovata Capital's Q4 2025 filing is one of the strangest and most revealing in the cycle: Spotify calls at the top, Ryanair and TSMC right behind, IBIT in the top four, and multiple option-heavy special-situation lines throughout the book.
Mar 6, 2026
TD Capital Management kept ITOT, VTI, BSV, and IVV at the center of the book, but Q4 2025 still carried a tactical growth message: Netflix up 881%, ServiceNow up 449%, Oracle up 274%.
Mar 6, 2026
SHP Wealth Management's Q4 2025 13F is one of the clearest ETF-model portfolios in the dataset: VOO at 27.4%, income and duration sleeves in the top five, and no meaningful stock-picking noise at the top.
Mar 6, 2026